New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2013
19:34 EDTONTY, CBI, SAPE, ACXM, LMCA, CSCO, SPPI, NQ, TSLAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cisco (CSCO), up 8.4%... Sapient (SAPE), up 6.3%. ALSO HIGHER: Tesla (TSLA), up 7.7% after announcing a common stock and debt securities shelf and disclosing that CEO Elon Musk is interested in purchasing up to 1.2M shares of the company's stock... Liberty Media (LMCA), up 3.9% after Berkshire Hathaway and SAC Capital disclosed new stakes in the company... Chicago Bridge & Iron (CBI), up 3.7% after Berkshire Hathaway announced a new stake in the company. DOWN AFTER EARNINGS: NetQin Mobile (NQ), down 8.3%... Acxiom (ACXM), down 4.1%. OTHER MOVERS: Oncothyreon (ONTY), up 7.6%, and Spectrum (SPPI), up 7.4%, after the release of abstracts for the American Society of Clinical Oncology annual meeting.
News For CSCO;SAPE;TSLA;LMCA;CBI;NQ;ACXM;ONTY;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 12, 2014
10:34 EDTTSLAOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
10:13 EDTCSCOEZchip expects revenue from Cisco to grow YoY in 2014
Comments taken from Q3 earnings conference call.
09:58 EDTCSCOCisco November volatility increases into Q1 and outlook
Cisco November weekly call option implied volatility is at 77, November is at 34, December is at 23, January is at 19, February is at 20; compared to its 26-week average of 23 according to Track Data, suggesting large near term price movement into the expected release of Q1 results after the market close on November 12.
09:37 EDTTSLAActive equity options trading
Active equity options trading according to Track Data: AAPL CLSN TWTR BABA NFLX TSLA AMZN CSIQ C
06:27 EDTCBICB&I sees FY15 EPS $5.75-$6.05, consensus $5.85
Sees FY15 revenue $14.8B-$15.2B, consensus $14.43B
06:27 EDTCBICB&I sees FY14 adjusted EPS $4.80-$5.65, consensus $5.18
Subscribe for More Information
November 11, 2014
16:01 EDTTSLAOptions Update; November 11, 2014
Subscribe for More Information
10:01 EDTCSCOInteractive Intelligence hires Jeff Platon as Chief Marketing Officer
Subscribe for More Information
09:37 EDTTSLAActive equity options trading
Subscribe for More Information
09:10 EDTNQNQ Mobile reaches agreement with Mobile Telesystems OSJC
Subscribe for More Information
08:08 EDTCBIChicago Bridge & Iron awarded contract by Calpine Mid-Merit
Subscribe for More Information
08:07 EDTCBIChicago Bridge & Iron awarded $40M contract by Coffeyville Resources
CB&I announced it has been awarded a contract valued in excess of $40M by Coffeyville Resources Refining & Marketing. The project scope includes the engineering, procurement, fabrication and field construction of a 22 million standard cubic feet per day hydrogen plant at its refinery in Coffeyville, Kansas.
November 10, 2014
16:28 EDTONTYOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
16:00 EDTTSLAOptions Update; November 10, 2014
Subscribe for More Information
15:43 EDTCBIAmerican Petroleum Institute to hold a conference
Subscribe for More Information
15:29 EDTCSCOCisco November volatility increases into Q1 and outlook
Subscribe for More Information
09:58 EDTCBIChicago Bridge & Iron volatility elevated into investor meeting
Subscribe for More Information
08:22 EDTCSCONetwork equipment makers slip after AT&T projects lower 2015 capital spending
Subscribe for More Information
08:03 EDTCBICB&I awarded plant services contract renewal by Arizona Public Service
Subscribe for More Information
07:12 EDTCSCOCA Technologies to hold a conference
CA World 2014 is being held in Las Vegas on November 9-12.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use